Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lukas M Carter

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 26, 2026
Efficacy of CLDN18.2-Targeted Radiotheranostics in Patient-Derived Models of Gastric CancerPaul C Klauser, Gina Dehlavi, Michele De Franco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
Trop-2.2 directed radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a pancreatic cancer modelEdwin C Pratt, David Bauer, Lukas M Carter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2025
Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In VivoHamid Reza Mirzaei, Samantha Lovibond, Leah Gajecki, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2022
Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancerJoshua A Korsen, Julia A Gutierrez, Kathryn M Tully, et al.
Theranostics|January 7, 2020
Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effectJeroen A C M Goos, Andrew Cho, Lukas M Carter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Delta-like Ligand 3-Directed <sup>225</sup>Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer ModelsTran T Hoang, David Bauer, Aidan Ingham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low ToxicityKathryn M Tully, Salomon Tendler, Lukas M Carter, et al.
Journal of Applied Clinical Medical Physics|January 27, 2026
Survey of normalized CTDI<sub>vol</sub> values across four major computed tomography vendors for use in the MIRDct softwareLaura E Dinwiddie, Jared M Baggett, James M Kofler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
IL13Rα2-Targeting Antibodies for Immuno-PET in Solid MalignanciesLeah Gajecki, Irina V Lebedeva, Yu-Rou Liao, et al.
Bioconjugate Chemistry|April 5, 2021
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy ApplicationsMegan M Dacek, Darren R Veach, Sarah M Cheal, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 26, 2026
Efficacy of CLDN18.2-Targeted Radiotheranostics in Patient-Derived Models of Gastric CancerPaul C Klauser, Gina Dehlavi, Michele De Franco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2026
Trop-2.2 directed radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a pancreatic cancer modelEdwin C Pratt, David Bauer, Lukas M Carter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2025
Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In VivoHamid Reza Mirzaei, Samantha Lovibond, Leah Gajecki, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2022
Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancerJoshua A Korsen, Julia A Gutierrez, Kathryn M Tully, et al.
Theranostics|January 7, 2020
Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effectJeroen A C M Goos, Andrew Cho, Lukas M Carter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 26, 2026
Delta-like Ligand 3-Directed <sup>225</sup>Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer ModelsTran T Hoang, David Bauer, Aidan Ingham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low ToxicityKathryn M Tully, Salomon Tendler, Lukas M Carter, et al.
Journal of Applied Clinical Medical Physics|January 27, 2026
Survey of normalized CTDI<sub>vol</sub> values across four major computed tomography vendors for use in the MIRDct softwareLaura E Dinwiddie, Jared M Baggett, James M Kofler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
IL13Rα2-Targeting Antibodies for Immuno-PET in Solid MalignanciesLeah Gajecki, Irina V Lebedeva, Yu-Rou Liao, et al.
Bioconjugate Chemistry|April 5, 2021
Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy ApplicationsMegan M Dacek, Darren R Veach, Sarah M Cheal, et al.
Pageof 7